MedKoo Cat#: 329884 | Name: Levomefolate calcium
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Levomefolate calcium, also known as LMCA and BAY 86-7660, is the calcium salt of 5-methyltetrahydrofolic acid, a biologically active form of folic acid that functions, in conjunction with Vitamin B12 , as a methyl-group donor involved in the conversion of homocysteine to methionine. Levomefolate is included in formulations of certain oral contraceptives to ensure adequate folic acid levels in women of child-bearing age to reduce the risk of neural tube defects.

Chemical Structure

Levomefolate calcium
Levomefolate calcium
CAS#151533-22-1 (calcium)

Theoretical Analysis

MedKoo Cat#: 329884

Name: Levomefolate calcium

CAS#: 151533-22-1 (calcium)

Chemical Formula: C20H23CaN7O6

Exact Mass: 497.1336

Molecular Weight: 497.52

Elemental Analysis: C, 48.28; H, 4.66; Ca, 8.06; N, 19.71; O, 19.29

Price and Availability

Size Price Availability Quantity
500mg USD 150.00 Ready to ship
1g USD 250.00 Ready to ship
2g USD 350.00 Ready to ship
5g USD 650.00 Ready to ship
10g USD 950.00 Ready to ship
Bulk Inquiry
Buy Now
Add to Cart
Synonym
BAY 86-7660; BAY-86-7660; BAY86-7660; BAY 867660; BAY-867660; BAY867660; Levomefolate calcium; LMCA; Bodyfolin, Deplin; L-Methylfolate calcium; Levomefolate calcium; Levomefolinate calcium
IUPAC/Chemical Name
calcium (4-((((S)-2-amino-5-methyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl)methyl)amino)benzoyl)-L-glutamate
InChi Key
VWBBRFHSPXRJQD-QNTKWALQSA-L
InChi Code
InChI=1S/C20H25N7O6.Ca/c1-27-12(9-23-16-15(27)18(31)26-20(21)25-16)8-22-11-4-2-10(3-5-11)17(30)24-13(19(32)33)6-7-14(28)29;/h2-5,12-13,22H,6-9H2,1H3,(H,24,30)(H,28,29)(H,32,33)(H4,21,23,25,26,31);/q;+2/p-2/t12-,13-;/m0./s1
SMILES Code
O=C1C2=C(NC[C@H](CNC3=CC=C(C(N[C@H](C([O-])=O)CCC([O-])=O)=O)C=C3)N2C)NC(N)=N1.[Ca+2]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Certificate of Analysis
Safety Data Sheet (SDS)
Biological target:
Levomefolate calcium is an artificial form of folate.
In vitro activity:
In addition, FA (folic acid) could ameliorate inflammation and decrease ROS production induced by Hcy. Furthermore, FA pre-treatment suppress palmitate -induced (NF-κB) p65 level in palmitate or Hcy stimulated cells. Reference: Arch Physiol Biochem. 2021 Feb 17:1-8. https://pubmed.ncbi.nlm.nih.gov/33596128/
In vivo activity:
FA (folic acid) significantly reduced the expression levels of nuclear factor-κ-gene binding (NF-κB) p65/Rela and interleukin-6 (IL-6) in rat arterial tissues, as well as the levels of plasma HHcy and serum malondialdehyde (MDA) in hypertension associated with HHcy rats (p < 0.05). Reference: Vascular. 2021 Aug 6:17085381211036549. https://pubmed.ncbi.nlm.nih.gov/34362270/
Solvent mg/mL mM comments
Solubility
Water 2.7 5.43
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 497.52 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Bagherieh M, Kheirollahi A, Zamani-Garmsiri F, Emamgholipour S, Meshkani R. Folic acid ameliorates palmitate-induced inflammation through decreasing homocysteine and inhibiting NF-κB pathway in HepG2 cells. Arch Physiol Biochem. 2021 Feb 17:1-8. doi: 10.1080/13813455.2021.1878539. Epub ahead of print. PMID: 33596128. 2. Yang H, Qin D, Xu S, He C, Sun J, Hua J, Peng S. Folic acid promotes proliferation and differentiation of porcine pancreatic stem cells into insulin-secreting cells through canonical Wnt and ERK signaling pathway. J Steroid Biochem Mol Biol. 2021 Jan;205:105772. doi: 10.1016/j.jsbmb.2020.105772. Epub 2020 Oct 19. PMID: 33091596. 3. Zhang L, Li Z, Xing C, Ma X, Xu R. The protective mechanism of folic acid on hyperhomocysteinemia-related arterial injury in spontaneously hypertensive rats: Folic acid against arterial inflammation. Vascular. 2021 Aug 6:17085381211036549. doi: 10.1177/17085381211036549. Epub ahead of print. PMID: 34362270. 4. Budni J, Moretti M, Freitas AE, Neis VB, Ribeiro CM, de Oliveira Balen G, Rieger DK, Leal RB, Rodrigues ALS. Behavioral and neurochemical effects of folic acid in a mouse model of depression induced by TNF-α. Behav Brain Res. 2021 Aug 3;414:113512. doi: 10.1016/j.bbr.2021.113512. Epub ahead of print. PMID: 34358572.
In vitro protocol:
1. Bagherieh M, Kheirollahi A, Zamani-Garmsiri F, Emamgholipour S, Meshkani R. Folic acid ameliorates palmitate-induced inflammation through decreasing homocysteine and inhibiting NF-κB pathway in HepG2 cells. Arch Physiol Biochem. 2021 Feb 17:1-8. doi: 10.1080/13813455.2021.1878539. Epub ahead of print. PMID: 33596128. 2. Yang H, Qin D, Xu S, He C, Sun J, Hua J, Peng S. Folic acid promotes proliferation and differentiation of porcine pancreatic stem cells into insulin-secreting cells through canonical Wnt and ERK signaling pathway. J Steroid Biochem Mol Biol. 2021 Jan;205:105772. doi: 10.1016/j.jsbmb.2020.105772. Epub 2020 Oct 19. PMID: 33091596.
In vivo protocol:
1. Zhang L, Li Z, Xing C, Ma X, Xu R. The protective mechanism of folic acid on hyperhomocysteinemia-related arterial injury in spontaneously hypertensive rats: Folic acid against arterial inflammation. Vascular. 2021 Aug 6:17085381211036549. doi: 10.1177/17085381211036549. Epub ahead of print. PMID: 34362270. 2. Budni J, Moretti M, Freitas AE, Neis VB, Ribeiro CM, de Oliveira Balen G, Rieger DK, Leal RB, Rodrigues ALS. Behavioral and neurochemical effects of folic acid in a mouse model of depression induced by TNF-α. Behav Brain Res. 2021 Aug 3;414:113512. doi: 10.1016/j.bbr.2021.113512. Epub ahead of print. PMID: 34358572.
1: Shelton RC, Pencina MJ, Barrentine LW, Ruiz JA, Fava M, Zajecka JM, Papakostas GI. Association of obesity and inflammatory marker levels on treatment outcome: results from a double-blind, randomized study of adjunctive L-methylfolate calcium in patients with MDD who are inadequate responders to SSRIs. J Clin Psychiatry. 2015 Dec;76(12):1635-41. doi: 10.4088/JCP.14m09587. PubMed PMID: 26613389. 2: Diefenbach K, Trummer D, Ebert F, Lissy M, Koch M, Rohde B, Blode H. EE-drospirenone-levomefolate calcium versus EE-drospirenone + folic acid: folate status during 24 weeks of treatment and over 20 weeks following treatment cessation. Int J Womens Health. 2013 Apr 11;5:149-63. doi: 10.2147/IJWH.S37254. Print 2013. PubMed PMID: 23610531; PubMed Central PMCID: PMC3628530. 3: Nelson AL. Comprehensive evaluation of Safyral(®) 2012. Womens Health (Lond). 2012 Nov;8(6):619-33. doi: 10.2217/whe.12.50. Review. PubMed PMID: 23181528. 4: Wiesinger H, Eydeler U, Richard F, Trummer D, Blode H, Rohde B, Diefenbach K. Bioequivalence evaluation of a folate-supplemented oral contraceptive containing ethinylestradiol/drospirenone/levomefolate calcium versus ethinylestradiol/drospirenone and levomefolate calcium alone. Clin Drug Investig. 2012 Oct 1;32(10):673-84. doi: 10.2165/11635280-000000000-00000. PubMed PMID: 22909145. 5: Fruzzetti F. Beyaz®: an oral contraceptive fortified with folate. Womens Health (Lond). 2012 Jan;8(1):13-9. doi: 10.2217/whe.11.68. Review. PubMed PMID: 22171769. 6: Bart S Sr, Marr J, Diefenbach K, Trummer D, Sampson-Landers C. Folate status and homocysteine levels during a 24-week oral administration of a folate-containing oral contraceptive: a randomized, double-blind, active-controlled, parallel-group, US-based multicenter study. Contraception. 2012 Jan;85(1):42-50. doi: 10.1016/j.contraception.2011.05.013. Epub 2011 Jul 13. PubMed PMID: 22067790. 7: Blode H, Klipping C, Richard F, Trummer D, Rohde B, Diefenbach K. Bioequivalence study of an oral contraceptive containing ethinylestradiol/drospirenone/levomefolate calcium relative to ethinylestradiol/drospirenone and to levomefolate calcium alone. Contraception. 2012 Feb;85(2):177-84. doi: 10.1016/j.contraception.2011.05.015. Epub 2011 Jul 19. PubMed PMID: 22067789. 8: Rapkin RB, Creinin MD. The combined oral contraceptive pill containing drospirenone and ethinyl estradiol plus levomefolate calcium. Expert Opin Pharmacother. 2011 Oct;12(15):2403-10. doi: 10.1517/14656566.2011.610791. Epub 2011 Aug 31. Review. PubMed PMID: 21877996.